MarketPulse

wet age-related macular degeneration

3 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

EyePoint Sets March 4 Earnings Call as Pipeline Advances Toward Key Milestones

EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.
EYPTbiopharmaceuticalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

4DMT to Present Pipeline Progress at Three Major Healthcare Conferences

4DMT will present pipeline progress at three major healthcare conferences in March 2026, showcasing late-stage programs including 4D-150 for retinal disease and 4D-710 for cystic fibrosis.
FDMTPhase 3 clinical trialinvestor conference